"tumour suppressor" trang 14 - tải miễn phí từ tailieuXANH
Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells

Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells
13    63    0
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer

Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer
12    56    0
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: A case report

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: A case report
5    79    0
Delays and routes to diagnosis of neuroendocrine tumours

Delays and routes to diagnosis of neuroendocrine tumours
8    145    0
Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer
17    61    0
‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment

‘DURVIT’: A phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour and lymph node microenvironment
8    64    0
CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
12    70    0
MiR-126 in intestinal-type sinonasal adenocarcinomas: Exosomal transfer of MiR-126 promotes anti-tumour responses

MiR-126 in intestinal-type sinonasal adenocarcinomas: Exosomal transfer of MiR-126 promotes anti-tumour responses
12    55    0
Combination of lutetium-177 labelled antiL1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: A novel combination against human ovarian carcinoma

Combination of lutetium-177 labelled antiL1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: A novel combination against human ovarian carcinoma
14    50    0
Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: An observational retrospective study with long-term follow-up

Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: An observational retrospective study with long-term follow-up
12    50    0
Combining genomic analyses with tumourderived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma

Combining genomic analyses with tumourderived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma
9    48    0
International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
11    58    0
N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer

N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer
16    79    0
Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers

Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers
15    63    0
Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing

Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing
13    67    0
Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated

Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated
13    59    0
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): Study protocol for a randomized controlled trial

Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): Study protocol for a randomized controlled trial
10    53    0
Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: A retrospective analysis of 448 cases

Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: A retrospective analysis of 448 cases
10    45    0
A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
8    43    0
Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells

Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells
10    47    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.